Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Development programme

ELIXA — lixisenatide cardiovascular outcomes

The first reported cardiovascular outcome trial of a GLP-1 receptor agonist. Its neutral result is the reason the Institute declines to treat cardiovascular benefit as a class effect.

The first reported cardiovascular outcome trial of a GLP-1 receptor agonist. Its neutral result is the reason the Institute declines to treat cardiovascular benefit as a class effect.

Sponsor class: Manufacturer-sponsored. First record: 2010.

Showing 0 records on this page

Records in this programme

5 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
ELIXALixisenatidePhase 3ReportedEvent-driven cardiovascular outcome trial6,0682015High
ELIXA-DDIprogramme recordLixisenatidePhase 1ReportedRandomised crossover—2015Very low
ELIXA-HEPATIC-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose—2015Very low
ELIXA-PKprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose—2015Very low
ELIXA-RENAL-IMPprogramme recordLixisenatidePhase 1ReportedPhase 1 ascending dose—2015Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.